Industry: Rapid liquid analysis

Andson Biotech is developing a device for real-time mass spectrometric analysis of the exterior of cells, called the Triple-shot Analysis System (TriAS). 

TriAS represents a significant improvement to existing technology. Normal analysis procedures of such cells can take days; Andson’s TriAS can deliver valuable biochemical information from a sample in around five minutes.

Biopharmaceutical workflows depend on fast and accurate electrospray ionization mass spectrometry. TriAS takes continuous or intermittent samples from a reactor at ultralow-flow rates for the process. This allows researchers to discern important biomarkers without disrupting R&D.

Notably, Andson won the Pitch Round at the 2022 CGHI Innovation Summit in Atlanta.

Company website: Andson

Back to companies